

**SPANISH VERSION**

**WOMEN'S INTERAGENCY HIV STUDY  
METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM**

ID LABEL HERE ---> |\_| - |\_|\_| - |\_|\_|\_|\_| - |\_|

VISIT #: \_\_\_\_\_ FORM COMPLETED BY: \_\_\_\_\_

VERSION DATE **10/01/07**

A1. DATE OF BLOOD DRAW: \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_  
M D Y

A2. ¿Usa Ud. insulina (ya sea por inyección o por inhalador) o toma alguna de las siguientes medicaciones por boca: thiazolidinedione [incluido pioglitazone (Actos) o rosiglitazone (Arandia)] o metformin (Glucophage) para la diabetes, o para controlar el azúcar en su sangre?  
 YES ..... 1  
 NO ..... 2

A3. ¿Está usted tomando actualmente alguna otra medicina que le hubieran recetado para la diabetes, o para bajar el azúcar en su sangre?  
 YES ..... 1  
 NO ..... 2 **(A6)**

A4. ¿Incluyó alguna de las siguientes?			i. Fecha de la última vez que la tomó	ii. Hora de la última vez que la tomó	iii. AM/PM INDICATOR
	<u>YES</u>	<u>NO</u>			
a. Acarbose (Precose) .....	1	2 <b>(b)</b>	____/____/____	_ _  :  _ _	AM.....1 PM.....2
b. Chlorpropamide (Diabinese) .....	1	2 <b>(c)</b>	____/____/____	_ _  :  _ _	AM.....1 PM.....2
c. Glimepiride (Amaryl) .....	1	2 <b>(d)</b>	____/____/____	_ _  :  _ _	AM.....1 PM.....2
d. Glipizide (Glucotrol) .....	1	2 <b>(e)</b>	____/____/____	_ _  :  _ _	AM.....1 PM.....2
e. Glyburide (Micronase, Diabeta) .....	1	2 <b>(g)</b>	____/____/____	_ _  :  _ _	AM.....1 PM.....2
g. Miglitol (Glyset) .....	1	2 <b>(h)</b>	____/____/____	_ _  :  _ _	AM.....1 PM.....2
h. Orlistat (Xenical) .....	1	2 <b>(j)</b>	____/____/____	_ _  :  _ _	AM.....1 PM.....2
j. Repaglinide (Prandin) .....	1	2 <b>(l)</b>	____/____/____	_ _  :  _ _	AM.....1 PM.....2
l. Starlix (Nateglinide) .....	1	2 <b>(m)</b>	____/____/____	_ _  :  _ _	AM.....1 PM.....2
m. Other SPECIFY: _____	1	2 <b>(A5)</b>	____/____/____	_ _  :  _ _	AM.....1 PM.....2

WIHS ID#

A5. IN THE LAST EIGHT (8) HOURS, HAS PARTICIPANT TAKEN ANY OF THE MEDICATIONS LISTED IN QUESTIONS A4a – A4I?

YES .....1 (PROMPT, BELOW)
NO.....2

PROMPT: IF PARTICIPANT HAS TAKEN ANY OF THE DIABETES MEDICATIONS LISTED IN QUESTIONS A4a – A4I IN THE LAST EIGHT (8) HOURS (A5 = 1), SHE MAY NOT PARTICIPATE IN THE GLUCOSE TOLERANCE TEST (GTT) AT THIS TIME. PLEASE RESCHEDULE THE PARTICIPANT FOR A GLUCOSE TOLERANCE TEST AND COMPLETE A NEW MS01 AT THAT TIME.

A6a. HAND PARTICIPANT ANTIVIRAL PHOTO MEDICATION CARDS. GO THROUGH CARDS WITH PARTICIPANT, SAYING THE NAME OF EACH DRUG ALOUD AND ASKING HER TO TELL YOU “YES” OR “NO” WHETHER SHE HAS TAKEN THIS DRUG IN THE LAST 3 DAYS. CHECK BELOW NEXT TO EACH DRUG PARTICIPANT REPORTS HAVING TAKEN. FOR DRUGS NOT LISTED, CHECK “OTHER ANTI-VIRAL,” RECORD NAME AS STATED BY PARTICIPANT AND FILL IN CORRESPONDING 3-DIGIT DRUG CODE FROM DRUG LIST 1.

Ahora le preguntaré acerca de cualquier medicamento que haya tomado en los últimos tres días para combatir el VIH/SIDA. Además de las medicinas recetadas, diga otros medicamentos que haya tomado como parte de un estudio, incluyendo estudios en los que no sabe si recibió el medicamento. En los últimos tres días, ha tomado usted...

Combination Medications

- 262 \_\_\_ Atripla (Sustiva + Viread + Emtriva)
227 \_\_\_ Combivir (AZT + 3TC)
254 \_\_\_ Epzicom (Ziagen + Efavirenz)
240 \_\_\_ Trizivir (abacavir + AZT + 3TC)
253 \_\_\_ Truvada (Viread + Emtriva)
280 \_\_\_ Complera (FTC + RPV + TDF)

Non-Nucleoside RTIs

- 255 \_\_\_ Intelence (etravirine, TMC 125)
194 \_\_\_ Rescriptor (delavirdine)
220 \_\_\_ Sustiva (efavirenz)
191 \_\_\_ Viramune (nevirapine)
276 \_\_\_ Edurant (rilpivirine, TMC 278)

Entry Inhibitors

- 233 \_\_\_ Fuzeon (T-20, enfuvirtide)
265 \_\_\_ Selzentry (maraviroc)

Protease Inhibitors

- 238 \_\_\_ Aptivus (tipranavir)
212 \_\_\_ Crixivan (indinavir)
210 \_\_\_ Invirase (saquinavir)
217 \_\_\_ Kaletra (lopinavir + ritonavir)
249 \_\_\_ Lexiva (fosamprenavir)
211 \_\_\_ Norvir (ritonavir)
256 \_\_\_ Prezista (TMC-114, darunavir)
243 \_\_\_ Reyataz (atazanavir)
216 \_\_\_ Viracept (nelfinavir)

Nucleoside/Nucleotide RTIs

- 239 \_\_\_ Emtriva (emtricitabine, FTC)
204 \_\_\_ Efavirenz (lamivudine, 3-TC)
092 \_\_\_ Retrovir (AZT, zidovudine, ZDV)
147 \_\_\_ Videx / Videx EC (didanosine, ddI)
234 \_\_\_ Viread (tenofovir)
159 \_\_\_ Zerit (stavudine, d4T)
218 \_\_\_ Ziagen (abacavir)

Other

- 207 \_\_\_ Droxia or Hydreia (hydroxyurea)
\_\_\_ Other anti-viral(s) (from Drug List 1)

Integrase Inhibitors

- 264 \_\_\_ Isentress (raltegravir, MK 0518)

Specify name of “other” antiviral:
Specify name of “other” antiviral:

→ Drug Code: |\_|\_|\_|\_|
→ Drug Code: |\_|\_|\_|\_|

b. ENTER THE TOTAL NUMBER OF MEDICATIONS THE PARTICIPANT REPORTED TAKING IN QUESTION A6a: |\_|\_|

PROMPT: IF QUESTION A6b = 0, SKIP TO QUESTION A8.



--

A10. ASK PARTICIPANT TO LIST ALL MEDICATIONS SHE HAS TAKEN IN THE LAST THREE DAYS, AND THE DATE/TIME SHE LAST TOOK EACH MEDICATION. COMPLETE COLUMNS a, b, c AND d.

START MS01s2

	a. DRUG NAME	b. DATE LAST TAKEN	c. TIME LAST TAKEN	d. AM/PM INDICATOR
i.	_____	___ \ ___ \ ___	_  :  _ _	AM.....1 PM.....2
ii.	_____	___ \ ___ \ ___	_  :  _ _	AM.....1 PM.....2
iii.	_____	___ \ ___ \ ___	_  :  _ _	AM.....1 PM.....2
iv.	_____	___ \ ___ \ ___	_  :  _ _	AM.....1 PM.....2
v.	_____	___ \ ___ \ ___	_  :  _ _	AM.....1 PM.....2
vi.	_____	___ \ ___ \ ___	_  :  _ _	AM.....1 PM.....2

END MS01s2

A10e. ENTER THE TOTAL NUMBER OF MEDICATIONS THE PARTICIPANT REPORTED TAKING IN QUESTION A10a:      |\_|\_|

**SECTION B. FIRST BLOOD DRAW (FASTING)**

B1. TIME OF FIRST BLOOD DRAW:      |\_|\_| : |\_|\_|      AM.....1  
PM .....2

B2. PHLEBOTOMIST'S INITIALS      \_\_\_\_\_

	TEST TYPE	TUBE TYPE	VOLUME	a.) SPECIMEN COLLECTED?		b.) REQUIRED VOLUME COLLECTED?		c.) ESTIMATED VOLUME COLLECTED?
				YES	NO	YES	NO	
B3.	GLUCOSE	Gray Top	2 ml	1	2 (i)	1 (B4)	2	_ _  mls.
		IF NO, SPECIFY REASON		i. _____				
B4.	INSULIN	Red-Top (SST)	4 ml	1	2 (i)	1 (PROMPT)	2	_ _  mls.
		IF NO, SPECIFY REASON		i. _____				

**PROMPT: IF QUESTION A2 = 1, SKIP TO PROMPT AT END OF FORM. OTHERWISE, PLEASE HAVE PATIENT DRINK 75G GLUCOSE LOAD WITHIN 5 MINUTES AND CONTINUE WITH SPECIMEN DRAW.**

B6. DID THE PARTICIPANT FULLY DRINK GLUCOSE (75G GLUCOSE LOAD)?

YES..... 1 **(B6a)**  
 NO..... 2

SPECIFY REASON: \_\_\_\_\_ **(END FORM)**

a. TIME GLUCOSE LOAD ADMINISTERED: |\_\_| |\_\_| : |\_\_| |\_\_| AM..... 1  
 PM ..... 2

**SECTION C. SECOND BLOOD DRAW (30 MINUTES)**

C1. TIME OF SECOND BLOOD DRAW: |\_\_| |\_\_| : |\_\_| |\_\_| AM..... 1  
 PM ..... 2

C2. PHLEBOTOMIST'S INITIALS \_\_\_\_\_

	<u>TEST TYPE</u>	<u>TUBE TYPE</u>	<u>VOLUME</u>	<u>a.) SPECIMEN COLLECTED?</u>		<u>b.) REQUIRED VOLUME COLLECTED?</u>		<u>c.) ESTIMATED VOLUME COLLECTED?</u>
				<u>YES</u>	<u>NO</u>	<u>YES</u>	<u>NO</u>	
C3.	GLUCOSE	Gray Top	2 ml	1	2 (i)	1 (C4)	2	__   __  mls.
		IF NO, SPECIFY REASON		i. _____				
C4.	INSULIN	Red-Top (SST)	4 ml	1	2 (i)	1 (D1)	2	__   __  mls.
		IF NO, SPECIFY REASON		i. _____				

**SECTION D. THIRD BLOOD DRAW (60 MINUTES)**

D1. TIME OF THIRD BLOOD DRAW: |\_\_| |\_\_| : |\_\_| |\_\_| AM..... 1  
 PM ..... 2

D2. PHLEBOTOMIST'S INITIALS \_\_\_\_\_

	<u>TEST TYPE</u>	<u>TUBE TYPE</u>	<u>VOLUME</u>	<u>a.) SPECIMEN COLLECTED?</u>		<u>b.) REQUIRED VOLUME COLLECTED?</u>		<u>c.) ESTIMATED VOLUME COLLECTED?</u>
				<u>YES</u>	<u>NO</u>	<u>YES</u>	<u>NO</u>	
D3.	GLUCOSE	Gray Top	2 ml	1	2 (i)	1 (E1)	2	__   __  mls.
		IF NO, SPECIFY REASON		i. _____				

WIHS ID #

**SECTION E. FOURTH BLOOD DRAW (120 MINUTES)**

E1. TIME OF FOURTH BLOOD DRAW: |\_\_| |\_\_| : |\_\_| |\_\_| AM.....1  
PM .....2

E2. PHLEBOTOMIST'S INITIALS      \_\_ \_ \_\_

	<u>TEST TYPE</u>	<u>TUBE TYPE</u>	<u>VOLUME</u>	<u>a.) SPECIMEN COLLECTED?</u>		<u>b.) REQUIRED VOLUME COLLECTED?</u>		<u>c.) ESTIMATED VOLUME COLLECTED?</u>
				<u>YES</u>	<u>NO</u>	<u>YES</u>	<u>NO</u>	
E3.	GLUCOSE	Gray Top	2 ml	1	2 (i)	1 (E4)	2	__   __  mls.
		IF NO, SPECIFY REASON		i. _____				
E4.	INSULIN	Red-Top (SST)	4 ml	1	2 (i)	1 (END)	2	__   __  mls.
		IF NO, SPECIFY REASON		i. _____				

**PROMPT: AFTER PROCESSING, SAMPLES FOR INSULIN AND GLUCOSE WILL BE BATCHED AND THEN SHIPPED TO QUEST DIAGNOSTICS. SEE THE WIHS MANUAL OF OPERATIONS, SECTION 25, FOR INSTRUCTIONS ON PROCESSING AND SHIPPING.**